Anti-hCD19 CAR IVT saRNA

saRNA self-amplifies within cells, making it reliable for sustained, high-level expression of transgenes. It can be applied in a range of applications, including gene regulation, vaccine development, and gene therapy, to elicit robust and long-lasting immune responses. Validated through in vitro expression, VectorBuilder’s anti-hCD19 CAR IVT saRNA encodes a CAR protein consisting of an scFv targeting human CD19, a CD28 transmembrane domain, and a co-stimulatory domain (CD28 or 4-1BB) fused to CD3ζ.

Ordering Information Price Match

Click here to view the amino acid sequence translated from Anti-hCD19-h28z CAR IVT saRNA >>
Click here to view the amino acid sequence translated from Anti-hCD19-hBBz CAR IVT saRNA >>

Shipping and storage

Our IVT saRNA products are stored in a 1 mM sodium citrate buffer (pH 6.4) and can be stored at -80°C for up to 12 months. RNA products are shipped on dry ice and freeze-thaw cycles should be avoided.

Experimental Validation

Expression of Anti-hCD19 CAR circRNA

Figure 1. Western blot analysis of CAR expression in vitro. HEK293 cells were transfected with anti-hCD19 CAR IVT mRNA or saRNA, and cellular proteins were collected 48 hours post-transfection for analysis. GAPDH served as the loading control, and CAR was detected with an anti-CD3 zeta (phospho Y142) antibody. The theoretical molecular weights of h28z and hBBz CARs are 54.26 kDa and 54.15 kDa, respectively. Our results indicate significantly higher CAR expression from saRNA than conventional mRNA.